The thesis

DexCom sells continuous glucose monitors and grows revenue 13.1% year over year with a 20.1% net margin and 62.5% gross margin. Analysts rate the stock a buy and pay 30.9 times earnings for that growth. Our conviction signal is dormant at 19 out of 100, so the setup is a strong business with weak near-term differentiation. The tension is real: GLP-1 adoption expands metabolic monitoring demand but may erode insulin-dependent CGM use, and the consensus buy case prices only the upside of that mix.

Why now

GLP-1 prescribing is shifting the diabetes population toward earlier-stage, non-insulin users, which decides whether DexCom's 13.1% growth accelerates or decays. A 30.9 times multiple on a dormant conviction signal leaves no margin for the bearish branch of that outcome.

What to watch

Quarterly revenue growth against the 13.1% baseline, split by new versus insulin-using patients, will show which GLP-1 effect dominates. Watch gross margin against 62.5% and any revision in the buy consensus for direction.

Key risks

If GLP-1 therapy reduces insulin initiation, DexCom loses its highest-intensity CGM users and the growth narrative breaks. At 30.9 times earnings and 13.1% growth, any deceleration compresses the multiple twice.Competitive pressure in CGM pricing could also cut the 62.5% gross margin.

Theme exposure

Upcoming catalysts